In Vitro System for Orally Inhaled Drug Release
Discover the development of an in vitro dissolution and release system from Nanopharm for OINDPs (orally inhaled drug products).
Regional Deposition in Generic Dry Powder Inhalers
Nanopharm investigate regional deposition and simulated inhaled pharmacokinetic profiles of generic dry powder inhalers.
Faster, Cost-Effective Alternative to Generic Bioequivalence
Discover SmartTrack to advance the development of OINDPs. Streamline inhalation and nasal therapies with optimized particle size distribution.
Mixed Kinetic Model of Inhaled Corticosteroid Dissolution
Explore the dissolution kinetics of inhaled pharmaceuticals in dry powder inhalers (DPI) and pressurized metered dose inhalers (pMDI).
Automated Classification of DPI Agglomerate Particles
Explore automated classification of dry powder inhaler particles using Cluster Analysis and Morphologically Directed Raman Spectroscopy.
Challenges in OINDPs Achieving Q3 Equivalence
Nanopharm review the bioequivalence challenges for OINDPs by achieving Q3 structural equivalence.
Trade Marks Registration Certificate for Nanopharm Ltd
Discover Nanopharm’s leading role in pharmaceutical research, specializing in OINDP, nasal, and inhaled pharmaceutical solutions.
Structural Dynamics of Fluticasone Propionate Processing
Nanopharm explores the effect of secondary processing on the structural relaxation dynamics of Fluticasone Propionate.
Secondary Processing’s Effect on Fluticasone Dynamics
Explore the effect of secondary processing on the structural relaxation dynamics of Fluticasone Propionate in DPIs.
Cohesive-Adhesive Balances in DPIs
Explore Dry Powder Inhaler development through Atomic Force Microscopy. Uncover Cohesive-Adhesive balances in OINDP for effective inhaler formulations.
